Urinary Excretion of Acetylamantadine by Cancer Patients

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators have determined that the drug amantadine hydrochloride is metabolized by acetylation by a specific enzyme named spermidine/spermine N-acetyltransferase (SSAT). This enzyme is increased in cancer cells. The investigators hypothesized that the amount of N-acetylamantadine excreted in urine during the first 12 hours after an oral dose would serve as a diagnostic biomarker for the presence of cancer in a human test subject.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Manitoba
• Collaborators: BioMark Technologies Inc.; Canadian Institutes of Health Research (CIHR)
• Treatments: Amantadine

Criteria

Inclusion Criteria:

• Either a medical diagnosis of cancer, or determination of general good health after a medical check-up within two weeks of participation in the study

Exclusion Criteria:

• Allergy to amantadine hydrochloride

• Chronic liver or kidney disease

• Chronic disease state not controlled by drug therapy, e.g. hypertension

• Pregnancy